Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Promitil,Capecitabine,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 23, 2020
Lead Product(s) : Promitil,Capecitabine,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?